Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review) DOI Creative Commons

Xinchi Luan,

Xuezhe Wang,

Gang Bian

et al.

Oncology Reports, Journal Year: 2024, Volume and Issue: 53(1)

Published: Nov. 20, 2024

Pancreatic ductal adenocarcinoma (PDAC) is a malignant neoplasm that typically manifests with subtle clinical manifestations in its early stages and frequently eludes diagnosis until the advanced phases of disease. The limited therapeutic options available for PDAC significantly contribute to high mortality rate, highlighting urgent need novel biomarkers capable effectively identifying facilitating precise diagnosis. pivotal role cellular exosomes both pathogenesis interventions has been underscored. Furthermore, researchers have acknowledged potential as targeted drug carriers against regulatory cells treating PDAC. present article aims provide comprehensive review encompassing recent advancements utilizing elucidating mechanisms underlying disease development, patterns metastasis, diagnostic techniques treatment strategies associated

Language: Английский

Liquid biopsy in pancreatic cancer – Current perspective and future outlook DOI
Ya-Ru Zhao, Jiajia Tang, Ke Jiang

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188868 - 188868

Published: Feb. 25, 2023

Language: Английский

Citations

25
Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma DOI Open Access

Gurkaranjot Singh,

Drew Kutcher,

Rajeshwar Lally

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 2101 - 2101

Published: May 31, 2024

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and currently third leading cause cancer-related death in United States after lung colon cancer. PDAC estimated to be second by 2030. The diagnosis at a late stage underlying for higher mortality poor prognosis surgery. Treatment resistance chemotherapy immunotherapy results recurrence surgery prognosis. Neoantigen burden CD8+ T-cell infiltration are associated with clinical outcomes paucity neoantigen-reactive tumor-infiltrating lymphocytes may treatment immunotherapy. This suggests need identify additional neoantigens therapies targeting these improve PDAC. In this review, we focus on describing pathophysiology, current strategies, followed target

Language: Английский

Citations

5
Novel Technologies for Exosome and Exosome-like Nanovesicle Procurement and Enhancement DOI Creative Commons
Andrés Martínez-Santillán, José González‐Valdez

Biomedicines, Journal Year: 2023, Volume and Issue: 11(5), P. 1487 - 1487

Published: May 19, 2023

Exosomes are extracellular nanovesicles commonly produced by mammalian cells that in recent years have risen as a novel strategy for drug delivery systems and cancer therapy because of their innate specificity high bioavailability. However, there limitations undermine potential. Among them is the lack mass production capacity with current available sources failure to reach intended therapeutic effect insufficient uptake or rapid clearance once administered. This review aims show advances overcoming these presenting, firstly, reported strategies improve exosome exosome-like nanovesicle extraction from possible eukaryotic sources, including animals, plants, protozoa; secondly, alternative modification methods functionalize exosomes conferring higher targeting protection organism defenses, which results an increase attachment ligands cellular inorganic materials. even when might address some obstacles procurement use, still several aspects need be addressed, so perspectives matter also presented analyzed throughout this work.

Language: Английский

Citations

13
Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation DOI Creative Commons
Stavros P. Papadakos, Nikolaos Machairas, Ioanna Ε. Stergiou

et al.

Cells, Journal Year: 2023, Volume and Issue: 12(16), P. 2036 - 2036

Published: Aug. 10, 2023

Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality rate and limited treatment options. Recent research has brought attention to the significant importance of intercellular communication in progression HCC, wherein exosomes have been identified as critical agents facilitating cell-to-cell signaling. In this article, we investigate impact macrophages both sources targets shedding light on intricate interplay between exosome-mediated macrophage involvement HCC pathogenesis. It investigates how derived from cells other cell types within tumor microenvironment (TME) can influence behavior, polarization, recruitment. Furthermore, section explores reciprocal interactions macrophage-derived cells, stromal immune elucidating their role growth, angiogenesis, metastasis, evasion. The findings presented here contribute better understanding offer new avenues for targeted interventions improved patient outcomes.

Language: Английский

Citations

13
The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment DOI Open Access
Stavros P. Papadakos, Nikolaos Dedes,

Nikolina Gkolemi

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 3015 - 3015

Published: Feb. 3, 2023

Pancreatic ductal adenocarcinoma (PDAC) is a major concern for health care systems worldwide, since its mortality remains unaltered despite the surge in cutting-edge science. The EPH/ephrin signaling system was first investigated 1980s. EPH/ephrins have been shown to exert bidirectional and cell-to-cell communication, influencing cellular morphology, adhesion, migration invasion. Recent studies highlighted critical role of various physiologic processes, including proliferation, survival, synaptic plasticity angiogenesis. Thus, it has become evident that may compelling effects on cell homeostasis contribute carcinogenesis. In particular, an impact pancreatic morphogenesis development, whereas several EPHs ephrins are altered PDAC. Several clinical preclinical attempted elucidate pathway, with multilayered PDAC development. These highly promising diagnosis, prognosis therapeutic management aim this review explore obscure aspects concerning physiology pancreas.

Language: Английский

Citations

11
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival DOI Creative Commons
Maria Urbanova, Marina Cihova, Verona Buociková

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 165, P. 115179 - 115179

Published: July 21, 2023

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers worldwide, primarily due to its robust desmoplastic stroma and immunosuppressive tumor microenvironment (TME), which facilitate progression metastasis. In addition, fibrous tissue leads sparse vasculature, high interstitial fluid pressure, hypoxia, thereby hindering effective systemic drug delivery immune cell infiltration. Thus, remodeling TME enhance perfusion, increase retention, reverse immunosuppression has become a key therapeutic strategy. recent years, targeting epigenetic pathways emerged as promising approach overcome cancer progression. Moreover, progress in nanotechnology provided new opportunities for enhancing efficacy of conventional drugs. Nano-based systems (NDDSs) offer several advantages, including improved pharmacokinetics, enhanced penetration, reduced toxicity. Smart NDDSs enable precise stromal components augment effectiveness immunotherapy through multiple options. This review offers an overview latest nano-based approaches developed achieve superior resistance. We specifically focus on epigenetic-targeted therapies context PDAC, discussing advantages limitations current strategies while highlighting developments. By emphasizing immense potential improving outcomes our paves way future research this rapidly evolving field.

Language: Английский

Citations

11
Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC DOI Creative Commons

Xing Liu,

Yidan Shao,

Yunjiang Li

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3379 - 3406

Published: March 1, 2025

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in world, mainly because its powerful pro-connective tissue proliferation matrix and immunosuppressive tumor microenvironment (TME), which promote progression metastasis. In addition, extracellular leads to vascular collapse, increased interstitial fluid pressure, obstruction lymphatic return, thereby hindering effective drug delivery, deep penetration, immune cell infiltration. Therefore, reshaping TME enhance perfusion, increase reverse suppression has become a key therapeutic strategy. Traditional therapies for PDAC, including surgery, radiation, chemotherapy, face significant limitations. Surgery challenging due location growth, while chemotherapy radiation are hindered by dense TME. recent years, advancement nanotechnology provided new opportunities improve efficacy. Nanoscale delivery systems (NDDSs) provide several advantages, improved stability vivo, enhanced reduced systemic toxicity. However, clinical translation PDAC therapy faces challenges. These include need precise targeting control over release, potential responses nanocarriers, scalability cost-effectiveness production. This article provides an overview latest nanobased methods achieving better outcomes overcoming resistance. We pay special attention TME-targeted context discuss advantages limitations current strategies, emphasize promising developments. By emphasizing enormous NDDSs improving treatment patients with critically discussing traditional challenges faced breakthroughs, our review paves way future research this rapidly developing field.

Language: Английский

Citations

0
Multi-omics of extracellular vesicles: An integrative representation of functional mediators and perspectives on lung disease study DOI Creative Commons
Yuexing Liu, Yixue Li, Tao Zeng

et al.

Frontiers in Bioinformatics, Journal Year: 2023, Volume and Issue: 3

Published: Feb. 9, 2023

Extracellular vesicles are secreted by almost all cell types. EVs include a broader component known as exosomes that participate in cell–cell and tissue–tissue communication via carrying diverse biological signals from one type or tissue to another. play roles messengers of the intercellular network mediate different physiological activities pathological changes. In particular, most natural carriers functional cargo such DNA, RNA, proteins, thus they relevant advancing personalized targeted therapies clinical practice. For application EVs, novel bioinformatic models methods based on high-throughput technologies multi-omics data required provide deeper understanding their biomedical characteristics. These qualitative quantitative representation for identifying markers, local cellular inference tracing origin production distant organ reconstruction targeting influential microenvironment transferable activators. Thus, this perspective paper introduces context provides an integrative viewpoint state current research applications.

Language: Английский

Citations

9
Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy DOI Creative Commons

Siheng Zhang,

Linglong Peng, Yifei Chen

et al.

Inflammation and Regeneration, Journal Year: 2024, Volume and Issue: 44(1)

Published: Nov. 4, 2024

Abstract Since chimeric antigen receptor T (CAR-T) cells were introduced three decades ago, the treatment using these has led to outstanding outcomes, and at moment, CAR-T cell therapy is a well-established mainstay for treating CD19 + malignancies multiple myeloma. Despite astonishing results of in B-cell-derived malignancies, several bottlenecks must be overcome promote its safety efficacy broaden applicability. These include cumbersome production process, concerns viral vectors, poor solid tumors, life-threatening side effects, dysfunctionality infused over time. Exosomes are nano-sized vesicles that secreted by all living play an essential role cellular crosstalk bridging between cells. In this review, we discuss how existing can focusing on exosomes. First, delve into effect tumor-derived exosomes function inhibiting their secretion enhance therapy. Afterward, application manufacturing non-viral approach discussed. We also review latest advancements ex vivo activation cultivation exosomes, as well potential engineered induction or boost proliferation Finally, CAR-engineered used versatile tool direct killing tumor delivering intended therapeutic payloads targeted manner.

Language: Английский

Citations

3
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer DOI Creative Commons

Mahrou Vahabi,

Annalisa Comandatore,

Chiara Centra

et al.

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 97, P. 50 - 67

Published: Nov. 11, 2023

Pancreatic ductal adenocarcinoma (PDAC) is an extremely deadly form of cancer, with limited progress in 5-year survival rates despite significant research efforts. The main challenges treating PDAC include difficulties early detection, and resistance to current therapeutic approaches due aggressive molecular microenvironment features. These emphasize the importance identifying clinically validated biomarkers for detection clinical management. Extracellular vesicles (EVs), particularly exosomes, have emerged as crucial mediators intercellular communication by transporting cargo. Recent has unveiled their role initiation, metastasis, chemoresistance PDAC. Consequently, utilizing EVs liquid biopsies holds promise identification prognosis, monitoring drug efficacy. However, numerous limitations, including isolation characterization homogeneous populations, well absence standardized protocols, can affect reliability studies involving biomarkers, underscoring necessity a prudent approach. also garnered considerable attention promising delivery system novel therapy tumors. loading biomolecules or chemical drugs into exosomes subsequent target cells effectively impede tumor progression. Nevertheless, there are obstacles that must be overcome ensure accuracy efficacy therapies relying on treatment In this review, we examine both recent advancements remaining obstacles, exploring potential biomarker discovery development vehicles.

Language: Английский

Citations

7